论文部分内容阅读
作者研究了急性心肌梗塞患者静脉应用前尿激酶的疗效、血栓选择性、溶解冠脉血栓的最低有效剂量, 9例急性心肌梗塞,相应冠脉阻塞。组1(4例)和组2(5例)分别静注前尿激酶4和7.5 mg,继以分别静滴11和40.5 mg,共60分钟。结果组1(本品总量15 mg)中无1例血栓溶解随后冠脉滴注链激酶25万U的3例中2例出现再灌注。组2(本品总量48 mg)中3例冠脉完全恢复通畅;另2例前尿激酶治疗失败者,随后冠脉滴注链激酶25万U亦未出现再灌注。前尿激酶治疗结束后,组1和组2血浆纤维蛋白原浓度分别降为治疗前的92±8%
The authors studied the efficacy of pre-application of urokinase in patients with acute myocardial infarction, thrombus selectivity, the lowest effective dose of coronary artery thrombosis, 9 acute myocardial infarction, and corresponding occlusion of the coronary arteries. Group 1 (4 patients) and group 2 (5 patients) were pre-primed with 4 and 7.5 mg of Urokinase, respectively, followed by intravenous infusion of 11 and 40.5 mg for 60 minutes, respectively. Results In group 1 (15 mg of the total product), none of the 3 patients underwent thrombolysis followed by coronary artery instillation of 250,000 U of streptokinase and 2 of the 3 patients showed reperfusion. In group 2 (the total amount of 48 mg), 3 cases of coronary artery completely recovered; the other 2 cases of former urokinase failure, followed by coronary streptokinase 250,000 U also did not appear reperfusion. After the pre-urokinase treatment, the concentrations of plasma fibrinogen in group 1 and group 2 were reduced to 92 ± 8% before treatment